Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Immunopathology of multiple sclerosis.
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo.
MS and NMO: Partners No More.
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.
Therapeutic effect of ghrelin in experimental autoimmune encephalomyelitis by inhibiting antigen-specific Th1/Th17 responses and inducing regulatory T cells.
Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis.
Placebo power.
Motor impairments at presentation of clinically isolated syndrome suggestive of multiple sclerosis: Characterization of different disease subtypes.
Transcriptional enhancers: from properties to genome-wide predictions.
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Information on natalizumab (marketed as Tysabri)
Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon.
Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis
Modulation of alertness by sustained cognitive demand in MS as surrogate measure of fatigue and fatigability.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.
Liver X receptors alpha and beta promote myelination and remyelination in the cerebellum.
Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases.
[Immunodepressive therapy in neurology].
Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions.
Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex.

Pages